Diltiazem hydrochloride 4% cream — Competitive Intelligence Brief

Diltiazem hydrochloride 4% cream (Diltiazem hydrochloride 4% cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Dermatology / Pain Management.

phase 3 Calcium channel blocker L-type calcium channels Dermatology / Pain Management Small molecule

Target snapshot

Diltiazem hydrochloride 4% cream (Diltiazem hydrochloride 4% cream) — S.L.A. Pharma AG. Diltiazem is a calcium channel blocker that reduces smooth muscle contraction and improves blood flow when applied topically to affected tissues.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Diltiazem hydrochloride 4% cream TARGET	Diltiazem hydrochloride 4% cream	S.L.A. Pharma AG	phase 3	Calcium channel blocker	L-type calcium channels
Losartan and amlodipine and hydrochlorothiazide	Losartan and amlodipine and hydrochlorothiazide	Hotel Dieu de France Hospital	marketed	Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic)	Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter
Perindopril plus Amlodipine	Perindopril plus Amlodipine	University of Abuja	marketed	ACE inhibitor + Calcium channel blocker combination	ACE (angiotensin-converting enzyme) and L-type calcium channels
Treatment T	Treatment T	Boryung Pharmaceutical Co., Ltd	marketed	Calcium channel blocker	L-type calcium channels
Nifedipine/Telmisartan	Nifedipine/Telmisartan	Bayer	marketed	Calcium channel blocker + Angiotensin II receptor blocker combination	L-type calcium channels; AT1 angiotensin II receptor
flunarizine and/or pregabalin	flunarizine and/or pregabalin	Taipei Veterans General Hospital, Taiwan	marketed	["Calcium Channel Blocker", "Anticonvulsant"]	["L-type calcium channels", "alpha2-delta subunit of voltage-gated calcium channels"]
Perindopril + amlodipine + if necessary, hydrochlorothiazide	Perindopril + amlodipine + if necessary, hydrochlorothiazide	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	marketed	ACE inhibitor + calcium channel blocker + thiazide diuretic combination	Angiotensin-converting enzyme (ACE), L-type calcium channels, sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker class)

1. Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
2. Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
3. Ain Shams University · 1 drug in this class
4. Bioprojet · 1 drug in this class
5. Bristol-Myers Squibb · 1 drug in this class
6. GlaxoSmithKline · 1 drug in this class
7. Handok Inc. · 1 drug in this class
8. Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
9. Hospital de Clinicas de Porto Alegre · 1 drug in this class
10. Laboratorios Richmond S.A.C.I.F. · 1 drug in this class